Search

Displaying results 5541 - 5550 of 7017 in total
  1. Drug

    Edasalonexent

    go.drugbank.com/drugs/DB15010
    Investigational

    Edasalonexent is under investigation in clinical trial NCT01511900 (A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes).

  2. Drug

    Pardoprunox

    go.drugbank.com/drugs/DB12061
    Investigational

    Pardoprunox is a partial dopamine D2 agonist and noradrenergic agonist with serotonin 5-HT1A agonist properties.

  3. Drug

    Tasimelteon

    go.drugbank.com/drugs/DB09071
    ApprovedInvestigational

    In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. … Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD).

  4. Drug

    Erteberel

    go.drugbank.com/drugs/DB07933
    Investigational

    Erteberel is an estrogen receptor beta agonist that has been used in trials studying the treatment of Benign Prostatic Hyperplasia.

  5. Drug

    Nevanimibe

    go.drugbank.com/drugs/DB16254
    Investigational

    Nevanimibe is under investigation in clinical trial NCT03053271 (A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome).

    Synonyms: Atr-101 free base
  6. Drug

    DCVax-L

    go.drugbank.com/drugs/DB17580
    Investigational

    DCVax-L is a personalized immunotherapy comprising an autologous vaccine with dendritic cells loaded _in vitro_ with autologous tumour lysate.

  7. Drug

    WVE-003

    go.drugbank.com/drugs/DB17870
    Investigational

    WVE-003 is an allele-selective antisense oligonucleotide that works to selectively reduce the toxic mutant huntingtin (mHTT) protein.[L46787]

  8. Drug

    AVB-001

    go.drugbank.com/drugs/DB18452
    Investigational

    AVB-001 is an encapsulated, engineered human ARPE-19 cell line that constitutively expresses the native human IL-2 cytokine

  9. Drug

    CSIC002

    go.drugbank.com/drugs/DB18584
    Experimental

    CSIC002 is a small-molecule Sema-3A inhibitor. It is being investigated for the treatment of anterior ischemic optic neuropathy.

  10. Drug

    Gatipotuzumab

    go.drugbank.com/drugs/DB18861
    Investigational

    Gatipotuzumab is under investigation in clinical trial NCT01899599 (Pankomab-gex™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer).